Swiss National Bank maintained its position in Albany Molecular Research Inc. (NASDAQ:AMRI) during the second quarter, Holdings Channel reports. The fund owned 43,300 shares of the company’s stock at the end of the second quarter. Swiss National Bank owned 0.13% of Albany Molecular Research worth $582,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in AMRI. BlackRock Fund Advisors raised its position in Albany Molecular Research by 0.8% in the first quarter. BlackRock Fund Advisors now owns 2,128,026 shares of the company’s stock worth $32,538,000 after buying an additional 17,274 shares during the period. Prudential Financial Inc. raised its position in Albany Molecular Research by 2.7% in the first quarter. Prudential Financial Inc. now owns 64,100 shares of the company’s stock worth $980,000 after buying an additional 1,700 shares during the period. Moody Aldrich Partners LLC raised its position in Albany Molecular Research by 169.3% in the second quarter. Moody Aldrich Partners LLC now owns 125,257 shares of the company’s stock worth $1,683,000 after buying an additional 78,752 shares during the period. Loomis Sayles & Co. L P purchased a new position in Albany Molecular Research during the first quarter worth approximately $965,000. Finally, NN Investment Partners Holdings N.V. purchased a new position in Albany Molecular Research during the first quarter worth approximately $770,000. Hedge funds and other institutional investors own 71.38% of the company’s stock.
Albany Molecular Research Inc. (NASDAQ:AMRI) traded down 0.91% during trading on Friday, reaching $16.31. 75,679 shares of the company’s stock were exchanged. The firm’s market cap is $563.17 million. The stock’s 50 day moving average price is $15.73 and its 200 day moving average price is $14.85. Albany Molecular Research Inc. has a 52-week low of $12.45 and a 52-week high of $20.65.
Albany Molecular Research (NASDAQ:AMRI) last released its quarterly earnings results on Thursday, August 4th. The company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.04. Albany Molecular Research had a negative net margin of 7.37% and a positive return on equity of 3.17%. The business had revenue of $116.50 million for the quarter, compared to analyst estimates of $123.10 million. Equities research analysts anticipate that Albany Molecular Research Inc. will post $1.07 EPS for the current fiscal year.
Separately, Morgan Stanley restated a “buy” rating and issued a $17.00 price target on shares of Albany Molecular Research in a research report on Friday, August 5th.
Albany Molecular Research Company Profile
Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).
Want to see what other hedge funds are holding AMRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albany Molecular Research Inc. (NASDAQ:AMRI).
Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.